Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5713402 | 0.85 | HPGD (0.63) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL7128929 | 0.81 | RAB9A (0.67) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7120002 | 0.78 | RAB9A (0.66) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7125386 | 0.78 | RAB9A (0.59) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27930260 | 0.78 | L3MBTL1 (0.63) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7125353 | 0.77 | RAB9A (0.59) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7127621 | 0.77 | ABL1 (0.63) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7128794 | 0.77 | MEN1 (0.69) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10965903 | 0.76 | RAB9A (0.78) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7130746 | 0.76 | RAB9A (0.69) | POLBMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973727-B8 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA INTERNATIONAL INC (BB) | 2006-01-18 | — | — | EP | disclosed |
| EP-0973727-B1 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA INC (CA) | 2005-10-26 | — | — | EP | disclosed |
| US-6780995-B2 | VIRICIDES; ANTICANCER AGENTS | ISOTECHNIKA INC. (CA) | 2004-08-24 | — | — | US | disclosed |
| US-20030187015-A1 | Activated iododerivatives for the treatment of cancer and aids | YATSCOFF RANDALL W (CA) | 2003-10-02 | — | — | US | disclosed |
| US-6511988-B2 | Prevention binding of transcription factor tozinc finger binding compounds | ISOTECHNIKA INC. (CA) | 2003-01-28 | — | — | US | disclosed |
| US-20020019538-A1 | Activated iododerivatives for the treatment of cancer and aids | ISOTECHNIKA INC. (CA) | 2002-02-14 | — | — | US | disclosed |
| US-6306871-B1 | IODONITROBENZAMIDE DERIVATIVES AS ANTICARCINOGENIC, ANTITUMOR AGENTS AND VIRICIDES | ISOTECHNIKA INC. (CA) | 2001-10-23 | — | — | US | disclosed |
| US-6225323-B1 | Activated iododerivatives for the treatment of cancer and AIDS | JOSEPH KOZIAK (CA) | 2001-05-01 | — | — | US | disclosed |
| EP-0973727-A2 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA,INC. (CA) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998045253-A1 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA, INC. (CA) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019538-A1 | Activated iododerivatives for the treatment of cancer and aids | IKZF3, ZC3HAV1, ZFP3 | POLB 656/4885MAPT 4672/4885MEN1 4088/4885 |
| US-20030187015-A1 | Activated iododerivatives for the treatment of cancer and aids | IKZF3, ZC3HAV1, ZFP3 | POLB 656/4885MAPT 4672/4885MEN1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.